William Blair Has Positive Forecast for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at William Blair lifted their Q1 2025 earnings estimates for shares of Biogen in a research report issued to clients and investors on Wednesday, February 12th. William Blair analyst M. Minter now forecasts that the biotechnology company will earn $3.87 per share for the quarter, up from their previous forecast of $3.82. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Biogen's current full-year earnings is $16.42 per share. William Blair also issued estimates for Biogen's Q3 2025 earnings at $3.53 EPS, Q4 2025 earnings at $3.94 EPS, FY2025 earnings at $15.54 EPS, Q3 2026 earnings at $3.01 EPS, Q4 2026 earnings at $4.00 EPS, FY2027 earnings at $17.41 EPS and FY2029 earnings at $18.73 EPS.

BIIB has been the subject of several other research reports. Scotiabank reduced their price target on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 13th. Sanford C. Bernstein assumed coverage on shares of Biogen in a report on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 price objective for the company. The Goldman Sachs Group cut their price objective on shares of Biogen from $281.00 to $245.00 and set a "buy" rating for the company in a report on Thursday, February 13th. TD Cowen cut their price objective on shares of Biogen from $300.00 to $275.00 and set a "buy" rating for the company in a report on Thursday, October 31st. Finally, Truist Financial cut their price objective on shares of Biogen from $220.00 to $210.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $211.85.

Biogen Price Performance

Shares of BIIB traded down $0.76 during mid-day trading on Friday, hitting $136.57. 1,327,009 shares of the company were exchanged, compared to its average volume of 1,414,183. Biogen has a 1-year low of $128.51 and a 1-year high of $238.00. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The company has a 50 day moving average of $146.52 and a 200-day moving average of $172.19. The stock has a market cap of $19.90 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently made changes to their positions in BIIB. Vanguard Group Inc. boosted its position in Biogen by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 16,748,875 shares of the biotechnology company's stock valued at $2,561,238,000 after buying an additional 70,368 shares during the period. State Street Corp raised its stake in Biogen by 3.5% during the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company's stock worth $1,423,747,000 after acquiring an additional 248,942 shares in the last quarter. Geode Capital Management LLC raised its stake in Biogen by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 3,695,476 shares of the biotechnology company's stock worth $563,709,000 after acquiring an additional 82,456 shares in the last quarter. Pacer Advisors Inc. raised its stake in Biogen by 13,574.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock worth $407,919,000 after acquiring an additional 2,648,024 shares in the last quarter. Finally, Norges Bank acquired a new position in Biogen in the fourth quarter valued at $355,569,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.